MIAMI Trial
|
WikiDoc Resources for MIAMI Trial |
|
Articles |
|---|
|
Most recent articles on MIAMI Trial Most cited articles on MIAMI Trial |
|
Media |
|
Powerpoint slides on MIAMI Trial |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on MIAMI Trial at Clinical Trials.gov Clinical Trials on MIAMI Trial at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on MIAMI Trial
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on MIAMI Trial Discussion groups on MIAMI Trial Patient Handouts on MIAMI Trial Directions to Hospitals Treating MIAMI Trial Risk calculators and risk factors for MIAMI Trial
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for MIAMI Trial |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
- MIAMI [1] [2] [3] [4] [5] [6] [7] [8]
- In the Metoprolol In Acute Myocardial Infarction (MIAMI) trial, STEMI patients were randomized to receive either metoprolol (up to 15 mg IV in 3 divided doses followed by 50 mg orally every six hours for 48 hours and then 100 mg twice per day thereafter) or placebo (n=5,700 patients). There was a favorable trend in mortality at 15 days (4.3% vs 4.9%) which was sustained over time. The benefits of metroprolol were greater in high risk patients. [6]
References
- ↑ "Metoprolol in acute myocardial infarction. Patient population. The MIAMI Trial Research Group". Am. J. Cardiol. 56 (14): 10G–14G. 1985. PMID 3933320. Unknown parameter
|month=ignored (help) - ↑ "Metoprolol in acute myocardial infarction. Other clinical findings and tolerability. The MIAMI Trial Research Group". Am. J. Cardiol. 56 (14): 39G–46G. 1985. PMID 3904393. Unknown parameter
|month=ignored (help) - ↑ "Metoprolol in acute myocardial infarction. Arrhythmias. The MIAMI Trial Research Group". Am. J. Cardiol. 56 (14): 35G–38G. 1985. PMID 3904392. Unknown parameter
|month=ignored (help) - ↑ "Metoprolol in acute myocardial infarction. Enzymatic estimation of infarct size. The MIAMI Trial Research Group". Am. J. Cardiol. 56 (14): 27G–29G. 1985. PMID 3904391. Unknown parameter
|month=ignored (help) - ↑ "Metoprolol in acute myocardial infarction. Development of myocardial infarction. The MIAMI Trial Research Group". Am. J. Cardiol. 56 (14): 23G–26G. 1985. PMID 3904390. Unknown parameter
|month=ignored (help) - ↑ 6.0 6.1 "Metoprolol in acute myocardial infarction. Mortality. The MIAMI Trial Research Group". Am. J. Cardiol. 56 (14): 15G–22G. 1985. PMID 3904389. Unknown parameter
|month=ignored (help) - ↑ "Metoprolol in acute myocardial infarction. Narcotic analgesics and other antianginal drugs. The MIAMI Trial Research Group". Am. J. Cardiol. 56 (14): 30G–34G. 1985. PMID 2865890. Unknown parameter
|month=ignored (help) - ↑ "Metoprolol in acute myocardial infarction. Patients and methods. The MIAMI Trial Research Group". Am. J. Cardiol. 56 (14): 3G–9G. 1985. PMID 2865889. Unknown parameter
|month=ignored (help)